TLR7 and breast cancer: In addition, treating invasive BC models with an intratumoral TLR agonist (PNP‐R848) retarded tumor growth and inhibited lung metastasis, and other investigators have further enhanced the antitumor effect by loading imidazoquinolines such as R848 as cyclic dinucleotides in biodegradable hydrogels or by tethering TLR7 agonists to oxaliplatin‐based platinum (IV) precursor drugs.281, 282, 283, 284, 285